Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820056 | 0.93 | MAPK1 (0.53) | MEN1KMT2AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2820085 | 0.86 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL693142 | 0.86 | L3MBTL1 (0.49) | MEN1KMT2AALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL2818868 | 0.85 | ALDH1A1 (0.58) | KMT2AALDH1A1L3MBTL1CYP3A4CYP2C9 | |
| SCHEMBL6642261 | 0.85 | L3MBTL1 (0.48) | MEN1KMT2AALDH1A1L3MBTL1TBXA2R | |
| SCHEMBL6642263 | 0.85 | L3MBTL1 (0.48) | MEN1KMT2AALDH1A1L3MBTL1TBXA2R | |
| SCHEMBL2824042 | 0.84 | L3MBTL1 (0.49) | MEN1KMT2AALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL2818837 | 0.84 | MAPT (0.54) | MEN1KMT2AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2819893 | 0.83 | L3MBTL1 (0.51) | MEN1KMT2AALDH1A1NPSR1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3014573 | 0.82 | L3MBTL1 (0.50) | MEN1KMT2AALDH1A1NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1849469-B1 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2010-10-27 | — | — | EP | claimed |
| US-7700586-B2 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | claimed |
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7700586-B2 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | CCR3, CCR1, CCR2 | MEN1 4873/4885KMT2A 2753/4885ALDH1A1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.